Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylamide SCHEMBL16402988 | 0.90 | ALDH1A1 (0.73) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL29092492 | 0.90 | ALDH1A1 (0.73) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL2160931 | 0.90 | ALDH1A1 (0.73) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL28918491 | 0.90 | ALDH1A1 (0.73) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL27770486 | 0.88 | ALDH1A1 (0.69) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL28734833 | 0.88 | ALDH1A1 (0.69) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL3255310 | 0.88 | ALDH1A1 (0.69) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL28807078 | 0.88 | ALDH1A1 (0.69) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL10661553 | 0.85 | ALDH1A1 (0.65) | ALDH1A1TSHRFGFR4LMNACA4 | |
| Acrylamide SCHEMBL4338828 | 0.85 | ALDH1A1 (0.65) | ALDH1A1TSHRFGFR4LMNACA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006026656-A1 | CYTOTOXIC NUCLEOSIDE ANALOG COMPOUND 003 FOR TREATING CANCER | PARKER HUGHES INSTITUTE (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060046972-A1 | Cytotoxic nucleoside analog compound 003 for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046972-A1 | Cytotoxic nucleoside analog compound 003 for treating cancer | NTPCR, ENTPD5, DUT | ALDH1A1 275/4885TSHR 4641/4885FGFR4 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.